Approvals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Novo Nordisk CSO: Hemophilia Treatment ‘Segmenting’ Much Like In Diabetes
Novo Nodisk's CSO says FDA approval of extended half-life Factor VIII Esperoct treatment for people with hemophilia A will give more choice to those patients and "effectively completes" the Danish group's hitherto R&D efforts based on clotting factor deficiencies.
Pipeline Watch: Phase III Starts In Prostate Cancer, C Diff Diarrhea
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Old Dog, New Tricks: Label Expansions Invigorate Diabetic Nephropathy Market
With four new entrants readying to be prescribed in the next four years, the market for diabetic nephropathy is looking more buoyant than ever. However, competition from GLP-1 agonists and eventually from generics could put a dampener on proceedings.
New Option For Uncontrolled Epilepsy On Horizon As US Accepts Cenobamate NDA
New potentially effective therapy for drug-resistant epilepsy, seen as the most pressing unmet need in this market, is on the horizon as FDA begins approval review of SK’s cenobamate, also marking a first for the Korean pharma industry.
Pipeline Watch: Top-Line Phase III Results With Isatuximab, Margetuximab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share
Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.
Pipeline Watch: Top-Line Phase III Results For Tanezumab, Dengue Vaccine, Ibrexafungerp
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Novo Nordisk Using Priority Review Voucher To Propel Oral Semaglutide To Market
Danish diabetes fighter will file oral semaglutide with FDA within months using a priority review voucher to reduce the time for expected approval to six months.
Generic Advair: Finally Approved, A Long Time Coming
Mylan's generic version of GlaxoSmithKline's blockbuster asthma drug was approved by the US FDA Jan. 30. Scrip's timeline tracks how the commercial value of the drug for GSK has greatly declined from its peak in 2013.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.